Physician profile
Tamara Goodman
NPI 1083094080
$2,267.04
in general payments reported to CMS, 2019-2025
27 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $344 · 2023: $300 · 2024: $525 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.13 | 2021-2025 | |
| Sk Life Science, INC. | $187.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $152.31 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $132.19 | 2021 | |
| Allergan, INC. | $111.29 | 2021-2022 | |
| Eisai INC. | $105.38 | 2021-2024 | |
| Pfizer INC. | $98.69 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $81.77 | 2021-2023 | |
| Lilly USA, LLC | $78.56 | 2022-2024 | Emgality |
| Neurelis, INC. | $64.08 | 2021-2024 | Valtoco |
| Alexion Pharmaceuticals, INC. | $62.74 | 2024-2025 | Ultomiris |
| Currax Pharmaceuticals LLC | $58.52 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $51.47 | 2025 | Ponvory |
| Ani Pharmaceuticals, INC. | $34.88 | 2024 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $34.09 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amylyx Pharmaceuticals, INC. | $33.81 | 2023 | Relyvrio |
| Lundbeck LLC | $32.16 | 2021-2025 | Vyepti |
| Amgen INC. | $31.98 | 2022 | |
| Aucta Pharmaceuticals, INC. | $29.21 | 2024 | Motpoly Xr |
| Otsuka America Pharmaceutical, INC. | $28.95 | 2024 | Rexulti |
| Livanova USA, INC. | $24.23 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $23.95 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.85 | 2023 | Ztlido |
| Catalyst Pharmaceuticals, INC. | $23.38 | 2021 | |
| Merz Pharmaceuticals, LLC | $21.72 | 2025 | Inbrija |
| Impel Pharmaceuticals INC. | $20.13 | 2023 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.